Iterex Enters Collaboration with AstraZeneca

Iterex Enters Collaboration with AstraZeneca in Respiratory Medicine
Iterex will help to further evaluate new asthma trial endpoint

Digital therapeutics company, Iterex will be working with AstraZeneca’s Innovative Medicine and Early Development (IMED) Biotech Unit in respiratory clinical trials to evaluate CompEx, a novel therapeutic endpoint for asthma. CompEx is an algorithm combining patient-recorded lung function deterioration, symptoms and use of reliever medication with the traditional measurement of severe exacerbations.

Dr. Sumanth Swaminathan, Chief Executive Officer, Iterex said, “This is a great opportunity for Iterex to leverage its triage algorithms in a respiratory trial. AstraZeneca has an exciting pipeline of investigational asthma therapies, and we are delighted to be partnering with them in this effort to transform asthma exacerbation trials.”

Dr. Carla A Da Silva, Director of Clinical Research, AstraZeneca said, “By using Iterex’s technology we are able to conduct real-time assessments of CompEx events. We are eager to evaluate how these correlate with patient health escalations, medication usage, and Iterex’s machine-learned triage prediction.”

In this collaboration, AstraZeneca’s clinical trial infrastructure will integrate with Iterex’s app to help accelerate the development of novel respiratory therapies in clinical trials. Initially, Iterex will provide its software platform and conduct real-time data analysis for one trial in Phase 2. Iterex will also provide device support and training for enrolling patients onto the platform.

About Iterex: Iterex is a digital therapeutics company that enables patients to self-manage their chronic lung or cardiovascular condition signs and symptoms. Iterex has a built-in machine learning feature that helps patients interpret troubling symptoms and signs with the goal of finding the right level of care earlier in their illness.